INTRODUCTION
Many translational and clinical cancer research efforts aim to identify biomarkers that may predict patients most likely to respond to treatment. The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have been studied extensively in clinical trials, [1] [2] [3] [4] [5] [6] [7] [8] and the association of EGFR-related biomarkers with EGFR-TKI clinical outcome has also been investigated.
Sensitivity to novel EGFR inhibitors may be influenced by a high EGFR gene copy number, with patients reported to experience increased gefitinib or erlotinib efficacy compared with a low EGFR gene copy number. [9] [10] [11] Mixed results have been reported for EGFR protein expression and response to EGFR-TKIs; no association was seen in the IRESSA Dose Evaluation in Advanced Lung Cancer (IDEAL) trials, 12 whereas others observed significant correlations between EGFR protein expression and response or survival with gefitinib and erlotinib. 9, 11, 13 Phospho-Akt expression also seems to correlate with improved clinical outcome with gefitinib, but only in the subgroup of patients who coexpress EGFR.
14 Activating EGFR mutations have been reported in many patients responding to EGFRTKIs, and seem to correlate with clinical response to EGFR-TKIs. [15] [16] [17] [18] [19] However, some patients without an EGFR mutation responded to EGFR-TKIs and some with an EGFR mutation failed to respond. 9, [20] [21] [22] To date, association between EGFR mutations and survival has been demonstrated mainly in Asian studies. 15, 17, 21 KRAS mutations have been associated with resistance to gefitinib and erlotinib, although EGFR and KRAS mutations seem mutually exclusive.
23 KRAS and BRAF mutations may result in constitutive signaling through the oncogenic Ras/Raf/Mek/Erk pathway, and more than 30 BRAF mutations have been identified with human cancers. 24, 25 The Iressa Survival Evaluation in Lung Cancer (ISEL) trial was a double-blind, placebo-controlled, parallel-group, multicenter, phase III survival study that randomly assigned 1,692 patients with previously treated, locally advanced or metastatic non-small-cell lung cancer in a 2:1 ratio to receive gefitinib 250 mg/d or placebo, plus best supportive care. 26 Gefitinib was associated with some improvement in survival in the overall (hazard ratio [HR] , 0.89; 95% CI, 0.77 to 1.02; P ϭ .087) and adenocarcinoma (HR, 0.84; 95% CI, 0.68 to 1.03; P ϭ .089) coprimary populations, but failed to reach statistical significance in the primary analysis using a log-rank test. Preplanned subset analyses showed marked heterogeneity in survival between patient groups, and never smokers (HR, 0.67; 95% CI, 0.49 to 0.92; P ϭ .012) or patients of Asian origin (HR, 0.66; 95% CI, 0.48 to 0.91; P ϭ .01) achieved a significant survival improvement with gefitinib versus placebo.
The ISEL study provides the first opportunity to assess the relationship between biomarkers (EGFR gene copy number; EGFR and phosphorylated Akt (p-Akt) protein expression; and EGFR, KRAS, and BRAF mutations) and clinical outcome after treatment with gefitinib in a placebo-controlled setting.
METHODS

Clinical Study Design
Full details of the ISEL study design have been published previously.
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Eligible patients had received one or two prior chemotherapy regimens but were refractory or intolerant to their most recent chemotherapy regimen.
Biomarker Analysis
All biomarkers were determined by technicians who were blind to clinical outcome and randomly assigned treatment. The quantity and quality of the tissue determined the analyses undertaken, prioritized as follows: EGFR protein expression; EGFR mutation; EGFR gene amplification; p-Akt protein expression; and KRAS and BRAF mutations. Some samples were unavailable for mutation analyses because of a lack of informed consent; hence, different numbers of samples were evaluated for each variable.
EGFR Gene Copy Number
EGFR gene copy number was assessed by fluorescent in situ hybridization (FISH) using LSI EGFR SpectrumOrange/CEP 7 SpectrumGreen probes (Vysis, Abbott Laboratories, Abbott Park, IL) as described.
9,10,27 Tumor samples had a high EGFR gene copy number if there was high polysomy (Ն four copies in Ն 40% of cells) or gene amplification (presence of tight gene clusters, a gene-to-chromosome ratio per cell of Ն 2, or Ն 15 copies of EGFR per cell in Ն 10% of cells analyzed).
Other Biomarkers
EGFR protein expression was assessed by immunohistochemistry using the EGFR pharmDX kit (DAKO, Glostrup, Denmark) . A positive tumor sample had staining in more than 10% of cells. Immunohistochemical analysis of p-Akt expression has been described previously.
9 EGFR mutations were analyzed primarily by DNA sequencing of exons 18 to 24, and secondarily using the amplification refractory mutation system (ARMS) assay (allelespecific polymerase chain reaction [PCR] ) to detect the exon 21 L858R point mutation and the most common exon 19 deletion (del G2235-A2249). Patients were mutation positive if a mutation in the EGFR gene was detected either by ARMS or by gene sequencing in both forward and reverse directions in at least two independent PCR products from tumor DNA. Sequence alterations detected in more than one amplicon were considered true mutations. Specific mutations in KRAS exon 2 (codon 12/13) and BRAF exon 15 (V599E) were identified as for EGFR mutations.
Statistical Analyses
To assess interaction strength between biomarker status and treatment (ie, if the treatment effect [HR] is different in positive-v negative-status patients), a Cox proportional hazards model was fitted to data from patients with assessable samples. The model included the six covariates from the primary analysis of the overall study (histology, sex, smoking history, refractory or intolerant to prior chemotherapy, number of prior chemotherapy regimens, and performance status); biomarker status; and interaction between biomarker status and treatment. P Ͻ .1 indicated a possible interaction.
Cox proportional hazards models investigated the treatment effect of gefitinib relative to placebo on survival in different subsets. HRs, 95% CIs, and P values were determined for the subgroups (positive, negative, and unknown) for each biomarker, and Kaplan-Meier curves were produced. Results in the unknown subsets were consistent with those in the overall population and therefore are not presented. Supportive analyses for time to treatment failure (TTF) and objective response rate were also conducted. If a biomarker had too few results for meaningful analysis, only a descriptive summary was produced.
RESULTS
Demographic and Biomarker Characteristics
Demographic characteristics for patients with assessable tissue samples for biomarker analysis were generally comparable to the overall ISEL population, although there were few samples from never smokers or patients of Asian origin (Table 1) . For patients assessable for EGFR gene copy number and EGFR and p-Akt protein expression, survival HRs generally were consistent with the overall population. However, the survival HRs from Cox regression analysis for patients assessable for EGFR, KRAS, and BRAF mutations were worse than the overall population, suggesting these subsets may not represent the overall population.
Of 1,692 patients randomly assigned, 460 (27.2%) had tissue samples assessable for one or more biomarker analyses: EGFR gene copy number (370 patients); EGFR protein (379 patients) and p-Akt protein expression (382 patients); EGFR (215 patients), KRAS (152 patients), and BRAF mutations (118 patients; Tables 1 and 2 ). The majority of patients with a high EGFR gene copy number were also positive for EGFR protein expression, and the majority of patients positive for EGFR mutation also had a high EGFR gene copy number and were positive for EGFR protein expression (Fig 1) .
Biomarker Analysis and Clinical Outcome
EGFR gene copy number. Altogether, 114 patients (30.8%) had a high EGFR gene copy number. They achieved significantly better survival with gefitinib compared with placebo than patients with a low EGFR gene copy number (comparison of HRs high v low copy number, P ϭ .045; Fig 2) . In patients with a high EGFR gene copy number, the risk of death during the follow-up period was 39% lower among patients receiving gefitinib compared with those receiving placebo (HR, 0.61; 95% CI, 0.36 to 1.04; P ϭ .067).
Median survival among patients with a high EGFR gene copy number was 8.3 and 4.5 months with gefitinib and placebo, respectively. No apparent difference in survival between gefitinib and placebo was observed in patients with a low EGFR gene copy number (HR, 1.16; 95% CI, 0.81 to 1.64; P ϭ .417). Consistent with overall survival, patients who had a high EGFR gene copy number seemed to achieve better objective response rate and TTF than those with a low EGFR gene copy number (Table 3) . After the results suggesting high EGFR gene copy number is predictive of a gefitinib-related treatment effect over placebo on overall survival, additional exploratory post-hoc analyses within subgroups were undertaken. HRs in favor of gefitinib-treated patients who had a high EGFR gene copy number were observed consistently across subgroups, even in patients with clinical factors usually considered to be least likely to benefit (eg, smokers and patients with nonadenocarcinoma; Table 4 ). With gefitinib, longer median survival was seen in patients with a high versus low EGFR gene copy number (8.3 v 4.3 months, respectively; HR, 0.78; 95% CI, 0.54 to 1.13). In contrast, with placebo, shorter median survival was seen in patients with a high versus low EGFR gene copy number (4.5 v 6.2 months, respectively; HR, 1.41; 95% CI, 0.84 to 2.35), indicating that the longer survival in gefitinib-treated patients with a high EGFR gene copy number was unlikely to be due to a prognostic effect.
EGFR protein expression. High EGFR protein expression was present in 264 patients (69.6%), and EGFR-positive patients achieved significantly better survival with gefitinib versus placebo than patients with EGFR protein expression-negative tumors (interaction test P ϭ .049; Fig 3) . The survival benefit for patients with EGFR protein expression-positive tumors treated with gefitinib (HR, 0.77; 95% CI, 0.56 to 1.08; P ϭ .126) was slightly greater than for the overall study population (Table 1) , with no evidence of a survival benefit of gefitinib to patients with EGFR protein expression-negative tumors (HR, 1.57; 95% CI, 0.86 to 2.87; P ϭ .140). EGFR protein expression-positive patients also seemed to achieve better response rates (8.2% v 1.5%) than EGFR protein expression-negative patients (Table 3) .
p-Akt protein expression. No relationship was observed between p-Akt status and survival outcome (interaction test P ϭ .778; Fig 4) . Although differences in response rates between gefitinib and placebo were slightly larger in p-Akt-positive than p-Akt-negative patients, there was no difference in overall survival or TTF (Table 3) . EGFR mutations. Of the 215 patients assessable for mutation detection, 26 (12.1%) were positive for EGFR mutation. Sequencing detected 16 EGFR mutations and ARMS detected 17 EGFR mutations (nine exon 21 L858R and eight exon 19 G2235-A2249 deletions). Furthermore, sequencing failed to detect 10 of these 17 mutations identified by ARMS, indicating ARMS is more sensitive than sequencing. Given that ARMS is designed to detect specific mutations, the use of sequencing was able to detect an additional six types of exon 19 deletions and four other point mutations. The EGFR mutations were distributed across exons 18, 19, and 21; the most frequently observed mutations were exon 19 deletions (14 patients [53.8%] with mutations) and exon 21 point mutations L858R/L861Q (11 patients [42.3%]) including one patient who had a double mutation delL747-P753 ins Q in exon 19 and L858R in exon 21. One patient (3.8%) had a G719A mutation in exon 18. Patients who were female, never smokers, of Asian origin, or had adenocarcinoma histology were more likely to have EGFR mutations than males, smokers, those of non-Asian origin, or patients with alternative histology (Fig 5) .
Objective tumor response rates with gefitinib were higher among patients positive for EGFR mutation (37.5%; six of 16 patients) than patients negative for EGFR mutation (2.6%; three of 116 patients). There were responders and nonresponders in both the patient group with exon 19 deletions and the group with exon 21 mutations. Evaluation of survival outcomes and TTF were limited because there were only 10 deaths (seven of 21 patients receiving gefitinib; three of five patients receiving placebo) and 15 treatment failures (11 of 21 patients receiving gefitinib; four of five patients receiving placebo) among the 26 patients with tumors positive for EGFR mutation. For patients with tumors negative for EGFR mutation, there were 130 deaths (93 of 132 patients receiving gefitinib; 37 of 57 patients receiving placebo) and 160 treatment failures (111 of 132 patients receiving gefitinib; 49 of 57 patients receiving placebo). However, the subgroup of patients assessable for mutation status may not represent the overall study population because the HR for this subgroup was worse than for the overall population.
KRAS and BRAF mutations. Five different KRAS mutations were detected in 12 of 152 (7.9%) patients, whereas no BRAF mutations were detected in 118 patients. No KRAS mutations were found in samples with an EGFR mutation, and 11 of 12 KRAS mutations were in samples from smokers. None of the six assessable patients treated with gefitinib who had a KRAS-positive mutation had a tumor response (response rate, 0%; 95% CI, 0 to 39.3), and seven of 87 patients treated with gefitinib who were negative for KRAS mutation had a tumor response (response rate, 8%; 95% CI, 3.3 to 15.9). The limited amount of data prevents meaningful evaluation of clinical outcomes in relation to these mutations. EGFR gene copy number is a predictor of survival benefit with gefitinib compared with placebo). The possible survival benefit in patients with a high EGFR gene copy number in ISEL is consistent with the erlotinib BR21 study, in which a high EGFR gene copy number was associated with significantly longer survival while receiving erlotinib versus placebo (HR, 0.44; 95% CI, 0.23 to 0.82; P ϭ .008) in univariate analysis. 11 BR21 univariate analysis showed no significant difference in survival with erlotinib versus placebo among patients with a low EGFR gene copy number (HR, 0.85; 95% CI, 0.48 to 1.51; P ϭ .59). Increased clinical benefit with gefitinib in patients with a high EGFR gene copy number has been reported in single-arm studies.
9,10 Additional validation is required to confirm whether EGFR gene copy number could be a biomarker to identify patients most likely to benefit from gefitinib. However, in this study, patients with a high EGFR gene copy number seemed to fare worse than patients with a low EGFR gene copy number in the placebo group, supporting previous findings from surgically resected patients that high EGFR gene copy number is associated with poorer prognosis in the absence of EGFR-TKI therapy.
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Some studies have reported that increased EGFR gene copy number is not associated with outcome after gefitinib therapy. 17, 20 However, in these studies EGFR gene copy number was evaluated by quantitative PCR, rather than by FISH; results with the two different techniques should not be compared with each other.
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In this study, an association was observed between EGFR protein expression and clinical outcome with gefitinib. This was also seen in BR21, in which patients with EGFR expression had significantly reduced risk of death with erlotinib versus placebo (HR, 0.68; 95% CI, 0.49 to 0.95; P ϭ .02). There was no evidence of a survival advantage for erlotinib versus placebo in patients with negative EGFR protein expression (HR, 0.93; 95% CI, 0.63 to 1.36; P ϭ .70). These studies suggest that patients with low EGFR gene copy number or who have negative EGFR protein expression seem unlikely to benefit from EGFR-TKIs. Another study from our group has shown that this is especially true when patients have both a low EGFR gene copy number and negative immunohistochemistry results.
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In our study we have used the DAKO antibody kit system for EGFR protein expression assessment. The 10% cutoff level for a positive result was chosen at the outset as the most discriminating cutoff limit based on previous studies. The same antibody and cutoff criteria were used in the erlotinib BR21 study, and both studies showed an association between EGFR protein expression and clinical outcome.
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In agreement with previously published reports, patients with EGFR mutations had higher response rates with gefitinib, compared with patients without EGFR mutations. 18, 19 For patients with EGFR mutations in ISEL, the clinical characteristics overlapped those associated with greater clinical benefit with gefitinib therapy (females, Asian origin, never smokers, adenocarcinoma histology). 22, 29 This was also observed in BR21, although both studies identified EGFR mutations in other patient subgroups. In ISEL, EGFR mutation status was much more closely linked to clinical characteristics than high EGFR gene copy number (Fig 5) .
Of the two methods we used to identify EGFR mutations, the primary sequencing method was useful for detecting novel or rarely observed mutations, and the secondary ARMS method was used as a more sensitive technique for the more common mutations. Our analysis demonstrates that combined use of direct sequencing and ARMS highlight and therefore aid our understanding of falsenegative results. Previous studies found an association between p-Akt and gefitinib sensitivity, 9,14 but this was not seen in our study. Differences in response rates between gefitinib and placebo were slightly larger in p-Akt-positive patients than in p-Akt-negative patients, but no difference in overall survival or TTF was seen. KRAS mutations may be associated with a lack of sensitivity to EGFR-TKIs, 23 but there were insufficient data from ISEL to allow meaningful evaluation of how KRAS and BRAF mutations correlate with clinical outcome.
Investigators face a number of challenges when trying to analyze biomarkers, including availability of tumor samples. Although this study had assessable tissue samples from 460 patients, this represented only 27.2% of the overall ISEL population of 1,692 patients. Demographic analysis revealed that few samples were available from never smokers or patients of Asian origin. Previous studies have shown that mutations were significantly more frequent in these patients. 30 Another aspect of biomarker analysis is that responsiveness to treatment with an EGFR-TKI may be due to a combination of various biologic factors. In this study, only 91 patients were assessable for all biomarkers and it was not feasible to conduct complex, multivariate analyses.
In conclusion, the biomarker analysis from ISEL showed that high EGFR gene copy number was a predictive biomarker for a gefitinib effect versus placebo on overall survival in the context of the largest data set explored yet in NSCLC. This is consistent with previous reports, and future studies should determine its value in identifying patients most likely to benefit from treatment with gefitinib. EGFR protein expression may also be associated with clinical benefit; patients who had a low EGFR gene copy number or were negative for EGFR protein expression seemed unlikely to benefit from treatment with gefitinib. Additional validation work is required to confirm the predictive value of a high EGFR gene copy number for treatment with an EGFR-TKI versus chemotherapy. 
